Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
70
days
Cost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18–64 years in Switzerland using PCV21
AuthorsMuloongo Simuzingili; Zinan Yi; Andrea Favre-Bulle; Thomas Mutschler; Eleana Tsoumani; Kwame Owusu-Edusei
Affiliations1. Merck & Co., Inc; 2. MSD Switzerland; 3. MSD Greece
114
days
Projected burden of bloodstream infections and the impact of molecular rapid diagnostic testing on costs and mortality in England and the United States (2025–2029): a population-level budget impact analysis
AuthorsJames K. Karichu; Mark Pennington; Kiera Lander; Tiffeny T. Smith; Adam Thornberg
Affiliations1. Roche Molecular Systems; 2. Source Health Economics; 3. Roche Diagnostics Corporation
62
days
Societal and fiscal gains from HPV vaccination in Poland – return on investment from extending access to HPV vaccination
AuthorsRafal Jaworski; Nikolaos Kotsopoulos; Marcin Czech; Mark P. Connolly; Andrew Pavelyev; Alicja Wojcik; Ugne Sabale
Affiliations1. Market Access Department, MSD; 2. Global Market Access Solutions Sàrl; 3. University of Athens; 4. Pharmacoeconomic Department, Institute of Mother and Child; 5. University Groningen; 6. Health Economic and Decision Sciences, Merck & Co., Inc; 7. Value & Implementation Outcomes Research, MSD Vilnius
41
days
Cost-effectiveness analysis of elranatamab versus physician’s choice of treatment (non–BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan
AuthorsAkira Yuasa; Mitsuhiro Nagano; Yoichi Kamei; Kengo Hatsuyama; Hiroyuki Matsuda; Patrick Hlavacek; Marco DiBonaventura; Kenshi Suzuki
Affiliations1. Japan Access & Value, Pfizer Japan Inc; 2. Pfizer R&D Japan G.K; 3. Real World Evidence Solutions & HEOR, IQVIA Solutions Japan G.K; 4. HTA, Value & Evidence, Pfizer Inc; 5. Myeloma/AL Amyloid Unit, Japanese Red Cross Medical Center
42
days
Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis
AuthorsTendai Mugwagwa; Benjamin A. Abramoff; Siddharth Karanth; Tram Nham; Ravi K. Goyal; Elizabeth Esterberg; Gurinder S. Sidhu; Alon Yehoshua; Ruth Mokgokong
Affiliations1. Pfizer Ltd; 2. University of Pennsylvania; 3. RTI Health Solutions; 4. Pfizer Inc
53
days
Cost-effectiveness analysis of Cardioform vs. Amplatzer: concerns regarding methodological transparency and interpretation of clinical results
AuthorsDavid W. Hutton; Anne M. Ryschon; Scott Goates; Jan B. Pietzsch; Lars Søndergaard
Affiliations1. Department of Health Management and Policy, University of Michigan; 2. Wing Tech Inc; 3. Global Data Science and Analysis; 4. Abbott, CA, USA
54
days
Budget impact analysis for albuterol–budesonide fixed-dose combination in the as needed treatment of adult patients with asthma in Kuwait
AuthorsGihan Hamdy Elsisi; Mohamed Al-Bader; Hanan Al-Razzuqi; Muneera Al-Asfoor; Nawaf Dehrab; Mohamed M. Ibrahim; Mona Al-Ahmad
Affiliations1. HTA Office, LLC; 2. Economics Department, American University; 3. Pulmonology Department, Seef Hospital; 4. Emergency Department, Farwaniya Hospital; 5. Emergency Department, Amiri Hospital; 6. Emergency Department, Adan Hospital; 7. Department of Medicine, Jaber Al-Ahmed Armed Forces Hospital, Ministry of Defense; 8. Pulmonology Department, Allergy Center
64
days
Cost-effectiveness of nicotine metabolite ratio-guided smoking cessation therapy in China: a hybrid decision-analytic modeling study based on real-world data
AuthorsAnqi Cheng; Min Wang; Yingman Gao; Tingfen Ji; Xuejun Hu; Xue Yu; Yong Qi; Wenli Chen; Suqin Xu; Zhao Liu; Xinmei Zhou; Dan Xiao; Chen Wang
Affiliations1. Department of Tobacco Control and Prevention of Respiratory Diseases, Center of Respiratory Medicine, China-Japan Friendship Hospital; 2. WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention; 3. National Center for Respiratory Medicine; 4. State Key Laboratory of Respiratory Health and Multimorbidity; 5. National Clinical Research Center for Respiratory Diseases; 6. China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College; 7. School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College; 8. Capital Medical University China-Japan Friendship School of Clinical Medicine; 9. Department of Respiratory and Critical Care Medicine, The First Hospital of China Medical University; 10. Department of Respiratory and Critical Care, Tengzhou Central People’s Hospital; 11. Department of Pulmonary and Critical Care Medicine, Henan Provincial People’s Hospital; 12. Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Chengde Medical College; 13. Department of Pulmonary and Critical Care Medicine, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology; 14. Peking Union Medical College, Chinese Academy of Medical Sciences
69
days
Costs and healthcare resource utilization after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis
AuthorsAlon Yehoshua; Rachel M. Black; Anan Zhou; Michelle A. Silver; Yu Han; Santiago M. C. Lopez; Benjamin Yarnoff; Rajeev M. Nepal; Maria M. Fernandez; Mohammad Ashraf Chaudhary; Tara Ahi
Affiliations1. Pfizer Inc; 2. AESARA Inc; 3. Genesis Research Group; 4. Thermo Fisher Scientific
105
days
Cell and gene therapies in managed care: US payer insights on coverage and financial risk
AuthorsElias C. Pittos; Joe DePinto
Affiliations1. McKesson
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days